Olink Reveal
Olink Reveal library
Consulteu els documents:
- SCTPG Olink Reveal assay list
Olink Reveal library includes 1.034 proteins selected for high-expected detectability in plasma, and focuses on biomarkers associated with inflammation and immune response that are of great interest in a wide range of disease groups.
The coverage analysis of Reactome pathways demonstrates that Reveal library offers excellent biological coverage, especially considering its much smaller size. Its carefully curated biomarkers content makes it a unique product for use in exploratory research across all major disease areas and biological questions, providing an affordable and accessible proteomics solution for a much broader sector of the scientific community.
The Olink Reveal library represents a carefully selected subset of the UKB-PPP proteomics data, the largest initiative to date linking circulating proteins to human disease. Using OlinkR Explore 3072, nearly 3,000 proteins were measured in plasma from more than 50,000 participants, and integrated with longitudinal healthcare records to estimate the impact of protein levels on future disease risk.
Diseases were grouped into major categories according to the PheWAS (Phenome-Wide Association Study) ontology. Each disease required ≥150 incident cases over a 10-year follow-up, with prevalent cases excluded. This classification provides a structured framework for evaluating protein–disease risk associations across diverse areas of human pathology.
Proteins showing robust associations with disease risk across multiple categories were prioritized for inclusion in Reveal library. It includes 29.4% of the 2,922 proteins measured in UKB-PPP and retains 35.7% of the statistically significant disease associations. Importantly, almost all (96.1%) diseases with significant protein association are covered by at least one protein in Olink Reveal.
This demonstrates the panel’s capacity to support research across a wide spectrum of diseases and biological processes.
- Olink Reveal is the most cost-effective Olink panel yet, and enables deep profiling of the proteome with as little as 4 μL of sample.
- The panel was informed by population-scale data from the UK Biobank Pharma Proteomics Project, ensuring that proteins included are biologically relevant and statistically associated with future disease risk. Is ideal for early discovery, feasibility studies, population-scale screens, and translational programs that require broad protein coverage without the complexity of ultra-high-plex panels.
- Olink Reveal provides a proteomic panel designed to understand the immunological complexity that drives much of human disease while also representing diverse biological pathways. This ensures broad applicability across research areas, from immune-mediated conditions to oncology, cardiovascular, neurological, and metabolic diseases.
- By uniting comprehensive pathway coverage with robust disease-association evidence and a streamlined PEA–NGS workflow, Olink Reveal empowers researchers to investigate immune complexity and broader disease biology at scale. This positions the panel as a versatile tool for exploratory studies, biomarker discovery, and the prioritization of therapeutic targets across nearly all research areas.